1
|
Lakhani N, Cosman R, Banerji U, Rasco D, Tomaszewska-Kiecana M, Garralda E, Kornacki D, Li J, Tian C, Bourayou N, Powderly J. A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101). ESMO Open 2024; 9:102254. [PMID: 38387109 PMCID: PMC11076959 DOI: 10.1016/j.esmoop.2024.102254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2023] [Revised: 12/12/2023] [Accepted: 01/14/2024] [Indexed: 02/24/2024] Open
Abstract
BACKGROUND Retifanlimab is a humanized, hinge-stabilized immunoglobulin G4κ monoclonal antibody against human programmed cell death protein 1 (PD-1). This first-in-human, phase I study assessed the safety and efficacy of retifanlimab in patients with advanced solid tumors and identified optimal dosing. PATIENTS AND METHODS POD1UM-101 was conducted in two parts: (i) dose escalation-evaluated retifanlimab [1 mg/kg every 2 weeks (q2w), 3 or 10 mg/kg q2w or every 4 weeks (q4w)] in patients with relapsed/refractory, unresectable, locally advanced or metastatic solid tumors; (ii) cohort expansion-biomarker-unselected tumor-specific cohorts [endometrial, cervical, sarcoma, non-small-cell lung cancer (NSCLC)] received retifanlimab 3 mg/kg q2w, and tumor-agnostic cohorts received flat dosing [375 mg every 3 weeks (q3w), or 500 and 750 mg q4w]. Primary objectives were safety and tolerability; secondary objective was efficacy in selected tumor types. RESULTS Thirty-seven patients were enrolled in dose escalation, 134 in PD-1 therapy-naïve tumor-specific cohort expansion (endometrial, n = 29; cervical, NSCLC, soft tissue sarcoma, each n = 35), and 45 in flat dosing (375 mg q3w, 500 and 750 mg q4w, each n = 15). No dose-limiting toxicities occurred during dose escalation; maximum tolerated dose was not reached and 3-mg/kg q2w expansion dose was selected based on safety and pharmacokinetic data. Immune-related adverse events were experienced by 40 patients (30%) in tumor-specific cohorts (most frequently hypothyroidism, hyperthyroidism, colitis, nephritis) and 6 (13%) in flat dosing (most frequently hypothyroidism, hyperthyroidism). Objective response rate (95% confidence interval) was 14% (4.8 to 30.3), 14% (3.9 to 31.7), 20% (8.4 to 36.9), and 3% (0.1 to 14.9) in advanced NSCLC, endometrial, cervical, and sarcoma tumor-specific cohorts that progressed after multiple prior systemic therapies. CONCLUSIONS Retifanlimab demonstrated clinical pharmacology, safety, and antitumor activity consistent with the programmed death (ligand)-1 inhibitor class. POD1UM-101 results support further exploration of retifanlimab as monotherapy and backbone immunotherapy in combination treatments, with recommended doses of 500 mg q4w and 375 mg q3w.
Collapse
Affiliation(s)
| | - R Cosman
- Medical Oncology, The Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, Darlinghurst, Australia; School of Medicine, University of New South Wales, Kensington, Australia
| | - U Banerji
- Drug Development Unit, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK
| | | | | | - E Garralda
- Early Drug Development Unit, Vall D'Hebron Institute of Oncology, Barcelona, Spain
| | | | - J Li
- Incyte Corporation, Wilmington, USA
| | - C Tian
- Incyte Corporation, Wilmington, USA
| | - N Bourayou
- Incyte Biosciences International Sàrl, Morges, Switzerland
| | - J Powderly
- Carolina BioOncology Institute, Huntersville, USA
| |
Collapse
|
2
|
Ingles Russo Garces A, Milite S, Oliveira E, Fernandez-Mateos J, Chen B, Pickard L, Stewart A, Lau R, De Haven Brandon A, Paranjape E, Sottoriva A, Banerjee S, Banerji U. 1697P Drug-induced evolutionary dynamics in BRCA-mutant/non-mutant ovarian cancer models. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1775] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
3
|
Coma S, Chowdhury S, Musteanu M, Stewart A, Pickard L, Krebs M, Minchom A, Banerji U, Barbacid M, Pachter J. P52.05 Dual RAF/MEK Inhibitor VS-6766 for Treatment of KRAS Mutant NSCLC: Novel Combinations Targeting G12C or G12V Variants. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.549] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
4
|
Banerjee S, Grochot R, Shinde R, Lima J, Krebs M, Rahman R, Little M, Tunariu N, Curcean A, Badham H, Mahmud M, Turner A, Parmar M, Yap C, Minchom A, Lopez J, de Bono J, Banerji U. 725MO Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
5
|
Saturno G, Lopes F, Niculescu-Duvaz I, Niculescu-Duvaz D, Zambon A, Davies L, Johnson L, Preece N, Lee R, Viros A, Holovanchuk D, Pedersen M, McLeary R, Lorigan P, Dhomen N, Fisher C, Banerji U, Dean E, Krebs MG, Gore M, Larkin J, Marais R, Springer C. The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers. Ann Oncol 2021; 32:269-278. [PMID: 33130216 PMCID: PMC7839839 DOI: 10.1016/j.annonc.2020.10.483] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2020] [Revised: 09/21/2020] [Accepted: 10/18/2020] [Indexed: 12/22/2022] Open
Abstract
BACKGROUND KRAS is mutated in ∼90% of pancreatic ductal adenocarcinomas, ∼35% of colorectal cancers and ∼20% of non-small-cell lung cancers. There has been recent progress in targeting G12CKRAS specifically, but therapeutic options for other mutant forms of KRAS are limited, largely because the complexity of downstream signaling and feedback mechanisms mean that targeting individual pathway components is ineffective. DESIGN The protein kinases RAF and SRC are validated therapeutic targets in KRAS-mutant pancreatic ductal adenocarcinomas, colorectal cancers and non-small-cell lung cancers and we show that both must be inhibited to block growth of these cancers. We describe CCT3833, a new drug that inhibits both RAF and SRC, which may be effective in KRAS-mutant cancers. RESULTS We show that CCT3833 inhibits RAF and SRC in KRAS-mutant tumors in vitro and in vivo, and that it inhibits tumor growth at well-tolerated doses in mice. CCT3833 has been evaluated in a phase I clinical trial (NCT02437227) and we report here that it significantly prolongs progression-free survival of a patient with a G12VKRAS spindle cell sarcoma who did not respond to a multikinase inhibitor and therefore had limited treatment options. CONCLUSIONS New drug CCT3833 elicits significant preclinical therapeutic efficacy in KRAS-mutant colorectal, lung and pancreatic tumor xenografts, demonstrating a treatment option for several areas of unmet clinical need. Based on these preclinical data and the phase I clinical unconfirmed response in a patient with KRAS-mutant spindle cell sarcoma, CCT3833 requires further evaluation in patients with other KRAS-mutant cancers.
Collapse
Affiliation(s)
- G Saturno
- Molecular Oncology Group, Cancer Research UK Manchester Institute, the University of Manchester, Alderley Park, Manchester, UK
| | - F Lopes
- Drug Discovery Unit, Cancer Research UK Manchester Institute, the University of Manchester, Alderley Park, Manchester, UK; Gene and Oncogene Targeting Team, CR-UK Cancer Therapeutics Unit, the Institute of Cancer Research, London, UK
| | - I Niculescu-Duvaz
- Gene and Oncogene Targeting Team, CR-UK Cancer Therapeutics Unit, the Institute of Cancer Research, London, UK
| | - D Niculescu-Duvaz
- Drug Discovery Unit, Cancer Research UK Manchester Institute, the University of Manchester, Alderley Park, Manchester, UK; Gene and Oncogene Targeting Team, CR-UK Cancer Therapeutics Unit, the Institute of Cancer Research, London, UK
| | - A Zambon
- Gene and Oncogene Targeting Team, CR-UK Cancer Therapeutics Unit, the Institute of Cancer Research, London, UK
| | - L Davies
- Gene and Oncogene Targeting Team, CR-UK Cancer Therapeutics Unit, the Institute of Cancer Research, London, UK
| | - L Johnson
- Gene and Oncogene Targeting Team, CR-UK Cancer Therapeutics Unit, the Institute of Cancer Research, London, UK
| | - N Preece
- Gene and Oncogene Targeting Team, CR-UK Cancer Therapeutics Unit, the Institute of Cancer Research, London, UK
| | - R Lee
- Molecular Oncology Group, Cancer Research UK Manchester Institute, the University of Manchester, Alderley Park, Manchester, UK
| | - A Viros
- Molecular Oncology Group, Cancer Research UK Manchester Institute, the University of Manchester, Alderley Park, Manchester, UK
| | - D Holovanchuk
- Molecular Oncology Group, Cancer Research UK Manchester Institute, the University of Manchester, Alderley Park, Manchester, UK
| | - M Pedersen
- Targeted Therapy Team, the Institute of Cancer Research, London, UK
| | - R McLeary
- Drug Discovery Unit, Cancer Research UK Manchester Institute, the University of Manchester, Alderley Park, Manchester, UK; Gene and Oncogene Targeting Team, CR-UK Cancer Therapeutics Unit, the Institute of Cancer Research, London, UK
| | - P Lorigan
- Division of Cancer Sciences, Faculty of Biology, Medicine and Health, the University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
| | - N Dhomen
- Molecular Oncology Group, Cancer Research UK Manchester Institute, the University of Manchester, Alderley Park, Manchester, UK
| | - C Fisher
- The Royal Marsden NHS Foundation Trust, London, UK
| | - U Banerji
- The Royal Marsden NHS Foundation Trust, London, UK
| | - E Dean
- Division of Cancer Sciences, Faculty of Biology, Medicine and Health, the University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
| | - M G Krebs
- Division of Cancer Sciences, Faculty of Biology, Medicine and Health, the University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
| | - M Gore
- The Royal Marsden NHS Foundation Trust, London, UK
| | - J Larkin
- The Royal Marsden NHS Foundation Trust, London, UK
| | - R Marais
- Molecular Oncology Group, Cancer Research UK Manchester Institute, the University of Manchester, Alderley Park, Manchester, UK.
| | - C Springer
- Drug Discovery Unit, Cancer Research UK Manchester Institute, the University of Manchester, Alderley Park, Manchester, UK; Gene and Oncogene Targeting Team, CR-UK Cancer Therapeutics Unit, the Institute of Cancer Research, London, UK.
| |
Collapse
|
6
|
Pal A, Stapleton S, Lai-Kwon J, Simoes N, Minchom A, Banerji U, de Bono J, Karikios D, Boyle F, Lopez J. 1886P Quantifying quality of informed consent (IC) in patients enrolled in phase I (ph I) oncology clinical trials with a validated instrument (QuIC Parts A, B) in a large United Kingdom phase I trials unit. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1533] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
7
|
Kolinsky MP, Rescigno P, Bianchini D, Zafeiriou Z, Mehra N, Mateo J, Michalarea V, Riisnaes R, Crespo M, Figueiredo I, Miranda S, Nava Rodrigues D, Flohr P, Tunariu N, Banerji U, Ruddle R, Sharp A, Welti J, Lambros M, Carreira S, Raynaud FI, Swales KE, Plymate S, Luo J, Tovey H, Porta N, Slade R, Leonard L, Hall E, de Bono JS. A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer. Ann Oncol 2020; 31:619-625. [PMID: 32205016 PMCID: PMC7217345 DOI: 10.1016/j.annonc.2020.01.074] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2019] [Revised: 01/16/2020] [Accepted: 01/29/2020] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND Activation of the PI3K/AKT/mTOR pathway through loss of phosphatase and tensin homolog (PTEN) occurs in approximately 50% of patients with metastatic castration-resistant prostate cancer (mCRPC). Recent evidence suggests that combined inhibition of the androgen receptor (AR) and AKT may be beneficial in mCRPC with PTEN loss. PATIENTS AND METHODS mCRPC patients who previously failed abiraterone and/or enzalutamide, received escalating doses of AZD5363 (capivasertib) starting at 320 mg twice daily (b.i.d.) given 4 days on and 3 days off, in combination with enzalutamide 160 mg daily. The co-primary endpoints were safety/tolerability and determining the maximum tolerated dose and recommended phase II dose; pharmacokinetics, antitumour activity, and exploratory biomarker analysis were also evaluated. RESULTS Sixteen patients were enrolled, 15 received study treatment and 13 were assessable for dose-limiting toxicities (DLTs). Patients were treated at 320, 400, and 480 mg b.i.d. dose levels of capivasertib. The recommended phase II dose identified for capivasertib was 400 mg b.i.d. with 1/6 patients experiencing a DLT (maculopapular rash) at this level. The most common grade ≥3 adverse events were hyperglycemia (26.7%) and rash (20%). Concomitant administration of enzalutamide significantly decreased plasma exposure of capivasertib, though this did not appear to impact pharmacodynamics. Three patients met the criteria for response (defined as prostate-specific antigen decline ≥50%, circulating tumour cell conversion, and/or radiological response). Responses were seen in patients with PTEN loss or activating mutations in AKT, low or absent AR-V7 expression, as well as those with an increase in phosphorylated extracellular signal-regulated kinase (pERK) in post-exposure samples. CONCLUSIONS The combination of capivasertib and enzalutamide is tolerable and has antitumour activity, with all responding patients harbouring aberrations in the PI3K/AKT/mTOR pathway. CLINICAL TRIAL NUMBER NCT02525068.
Collapse
Affiliation(s)
- M P Kolinsky
- The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK; Cross Cancer Institute, Edmonton, Canada
| | - P Rescigno
- The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK; Department of Clinical Medicine and Surgery, Department of Translational Medical Sciences, AOU Federico II, Naples, Italy
| | - D Bianchini
- The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK
| | - Z Zafeiriou
- The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK
| | - N Mehra
- The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK
| | - J Mateo
- The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK
| | - V Michalarea
- The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK
| | - R Riisnaes
- The Institute of Cancer Research, London, UK
| | - M Crespo
- The Institute of Cancer Research, London, UK
| | | | - S Miranda
- The Institute of Cancer Research, London, UK
| | | | - P Flohr
- The Institute of Cancer Research, London, UK
| | - N Tunariu
- The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK
| | - U Banerji
- The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK
| | - R Ruddle
- The Institute of Cancer Research, London, UK
| | - A Sharp
- The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK
| | - J Welti
- The Institute of Cancer Research, London, UK
| | - M Lambros
- The Institute of Cancer Research, London, UK
| | - S Carreira
- The Institute of Cancer Research, London, UK
| | - F I Raynaud
- The Institute of Cancer Research, London, UK
| | - K E Swales
- The Institute of Cancer Research, London, UK
| | - S Plymate
- University of Washington School of Medicine, Seattle, USA
| | - J Luo
- Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, USA
| | - H Tovey
- The Institute of Cancer Research, London, UK
| | - N Porta
- The Institute of Cancer Research, London, UK
| | - R Slade
- The Institute of Cancer Research, London, UK
| | - L Leonard
- The Institute of Cancer Research, London, UK
| | - E Hall
- The Institute of Cancer Research, London, UK
| | - J S de Bono
- The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK.
| |
Collapse
|
8
|
Banerjee S, Lewsley LA, Clamp A, krell J, Herbertson R, Glasspool R, Orbegoso C, Green C, Kristeleit R, Gourley C, Cambell C, Banerji U, Shepherd C, Brugger W, Chudleigh L, Hanif A, McNeish I, Paul J. OCTOPUS: A randomised, multi-centre phase II umbrella trial of weekly paclitaxel+/- novel agents in platinum-resistant ovarian cancer: Vistusertib. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz250.001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
9
|
Scaranti M, Caldwell R, Miralles MS, Shinde R, Pal A, Ang J, Biondo A, Guo C, Cojocaru E, Gennatas S, Lockie F, Bertan C, Baker C, Carreira S, Banerjee S, Kaye S, de Bono J, Banerji U, Minchom A, Lopez J. Clinical impact of molecular profiling of cervical cancer (CC) patients (pts) in a dedicated phase I (P1) unit. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz250.063] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
10
|
Cook N, Banerji U, Evans J, Biondo A, Germetaki T, Randhawa M, Godfrey L, Leslie S, Jeffrey P, Rigby M, Bennett G, Blakemore S, Koehler M, Niewiarowski A, Pittman M, Symeonides S. Pharmacokinetic (PK) assessment of BT1718: A phase I/II a study of BT1718, a first in class bicycle toxin conjugate (BTC), in patients (pts) with advanced solid tumours. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz244.026] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
11
|
Georgiou A, Stewart A, Thavasu P, Coker E, Poelsterl S, Al-Lazikani B, Cunningham D, Whittaker S, Banerji U. KRAS mutant and RAS/BRAF wild type colorectal cancer cells exhibit differences in the rewiring of signal transduction that can impact on future therapeutic strategies. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy268] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
12
|
Basu B, Krebs MG, Sundar R, Wilson RH, Spicer J, Jones R, Brada M, Talbot DC, Steele N, Ingles Garces AH, Brugger W, Harrington EA, Evans J, Hall E, Tovey H, de Oliveira FM, Carreira S, Swales K, Ruddle R, Raynaud FI, Purchase B, Dawes JC, Parmar M, Turner AJ, Tunariu N, Banerjee S, de Bono JS, Banerji U. Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. Ann Oncol 2018; 29:1918-1925. [PMID: 30016392 PMCID: PMC6158767 DOI: 10.1093/annonc/mdy245] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Background We have previously shown that raised p-S6K levels correlate with resistance to chemotherapy in ovarian cancer. We hypothesised that inhibiting p-S6K signalling with the dual m-TORC1/2 inhibitor in patients receiving weekly paclitaxel could improve outcomes in such patients. Patients and methods In dose escalation, weekly paclitaxel (80 mg/m2) was given 6/7 weeks in combination with two intermittent schedules of vistusertib (dosing starting on the day of paclitaxel): schedule A, vistusertib dosed bd for 3 consecutive days per week (3/7 days) and schedule B, vistusertib dosed bd for 2 consecutive days per week (2/7 days). After establishing a recommended phase II dose (RP2D), expansion cohorts in high-grade serous ovarian cancer (HGSOC) and squamous non-small-cell lung cancer (sqNSCLC) were explored in 25 and 40 patients, respectively. Results The dose-escalation arms comprised 22 patients with advanced solid tumours. The dose-limiting toxicities were fatigue and mucositis in schedule A and rash in schedule B. On the basis of toxicity and pharmacokinetic (PK) and pharmacodynamic (PD) evaluations, the RP2D was established as 80 mg/m2 paclitaxel with 50 mg vistusertib bd 3/7 days for 6/7 weeks. In the HGSOC expansion, RECIST and GCIG CA125 response rates were 13/25 (52%) and 16/25 (64%), respectively, with median progression-free survival (mPFS) of 5.8 months (95% CI: 3.28-18.54). The RP2D was not well tolerated in the SqNSCLC expansion, but toxicities were manageable after the daily vistusertib dose was reduced to 25 mg bd for the following 23 patients. The RECIST response rate in this group was 8/23 (35%), and the mPFS was 5.8 months (95% CI: 2.76-21.25). Discussion In this phase I trial, we report a highly active and well-tolerated combination of vistusertib, administered as an intermittent schedule with weekly paclitaxel, in patients with HGSOC and SqNSCLC. Clinical trial registration ClinicialTrials.gov identifier: CNCT02193633.
Collapse
Affiliation(s)
- B Basu
- Department of Oncology, University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge
| | - M G Krebs
- Manchester Academic Health Science Centre, The University of Manchester and The Christie NHS Foundation Trust, Manchester
| | - R Sundar
- Drug Development Unit, The Institute of Cancer Research and The Royal Marsden, London, UK; Department of Haematology-Oncology, National University Health System, Singapore
| | - R H Wilson
- Centre for Cancer Research and Cell Biology, Queen's University Belfast and Belfast City Hospital, Belfast
| | - J Spicer
- School of Cancer and Pharmaceutical Sciences, King's College London and Guy's and St Thomas' NHS Foundation Trust, London
| | - R Jones
- Cardiff University and Velindre Cancer Centre, Cardiff
| | - M Brada
- University of Liverpool and Clatterbridge Cancer Centre NHS Foundation Trust, Wirral
| | - D C Talbot
- Department of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford
| | - N Steele
- University of Glasgow and Beatson West of Scotland Cancer Centre, Glasgow
| | - A H Ingles Garces
- Drug Development Unit, The Institute of Cancer Research and The Royal Marsden, London, UK
| | - W Brugger
- Oncology, IMED Biotech Unit AstraZeneca, Cambridge
| | | | - J Evans
- University of Glasgow and Beatson West of Scotland Cancer Centre, Glasgow
| | - E Hall
- Clinical Trials and Statistics Unit, The Institute of Cancer Research, London
| | - H Tovey
- Clinical Trials and Statistics Unit, The Institute of Cancer Research, London
| | - F M de Oliveira
- Division of Clinical Studies, The Institute of Cancer Research, London
| | - S Carreira
- Division of Clinical Studies, The Institute of Cancer Research, London
| | - K Swales
- Division of Cancer Therapeutics, The Institute of Cancer Research, London
| | - R Ruddle
- Drug Development Unit, The Institute of Cancer Research and The Royal Marsden, London, UK; Division of Cancer Therapeutics, The Institute of Cancer Research, London
| | - F I Raynaud
- Drug Development Unit, The Institute of Cancer Research and The Royal Marsden, London, UK; Division of Cancer Therapeutics, The Institute of Cancer Research, London
| | - B Purchase
- Drug Development Unit, The Institute of Cancer Research and The Royal Marsden, London, UK
| | - J C Dawes
- Drug Development Unit, The Institute of Cancer Research and The Royal Marsden, London, UK
| | - M Parmar
- Drug Development Unit, The Institute of Cancer Research and The Royal Marsden, London, UK
| | - A J Turner
- Drug Development Unit, The Institute of Cancer Research and The Royal Marsden, London, UK
| | - N Tunariu
- Drug Development Unit, The Institute of Cancer Research and The Royal Marsden, London, UK
| | - S Banerjee
- Department of Gynae-Oncology, The Royal Marsden, London, UK
| | - J S de Bono
- Drug Development Unit, The Institute of Cancer Research and The Royal Marsden, London, UK; Division of Clinical Studies, The Institute of Cancer Research, London
| | - U Banerji
- Drug Development Unit, The Institute of Cancer Research and The Royal Marsden, London, UK; Division of Clinical Studies, The Institute of Cancer Research, London; Division of Cancer Therapeutics, The Institute of Cancer Research, London.
| |
Collapse
|
13
|
Dillon M, Boylan Z, Smith D, Guevara J, Mohammed K, Peckitt C, Saunders M, Banerji U, Clack G, Smith S, Spicer J, Forster M, Harrington K. PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours. Clin Transl Radiat Oncol 2018; 12:16-20. [PMID: 30073210 PMCID: PMC6068075 DOI: 10.1016/j.ctro.2018.06.001] [Citation(s) in RCA: 63] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2018] [Accepted: 06/06/2018] [Indexed: 12/19/2022] Open
Abstract
PATRIOT is a phase I study of the ATR inhibitor, AZD6738, as monotherapy, and in combination with palliative radiotherapy. Here, we describe the protocol for this study, which opened in 2014 and is currently recruiting and comprises dose escalation of both drug and radiotherapy, and expansion cohorts.
Collapse
Affiliation(s)
- M.T. Dillon
- The Institute of Cancer Research, London, UK
- The Royal Marsden NHS Foundation Trust, London, UK
| | | | - D. Smith
- The Royal Marsden NHS Foundation Trust, London, UK
| | - J. Guevara
- The Royal Marsden NHS Foundation Trust, London, UK
| | - K. Mohammed
- The Royal Marsden NHS Foundation Trust, London, UK
| | - C. Peckitt
- The Royal Marsden NHS Foundation Trust, London, UK
| | | | - U. Banerji
- The Royal Marsden NHS Foundation Trust, London, UK
| | - G. Clack
- Department of Oncology and Metabolism, University of Sheffield Medical School, Beech Hill Road, SHEFFIELD S10 2RX, UK
| | | | | | - M.D. Forster
- University College London Hospitals NHS Foundation Trust and UCL Cancer Centre, London UK
| | - K.J. Harrington
- The Institute of Cancer Research, London, UK
- The Royal Marsden NHS Foundation Trust, London, UK
| |
Collapse
|
14
|
Acar A, Nichol D, Thavasu P, Sagastume I, Mateos J, Stubbs M, Burke R, Maley C, Banerji U, Sottoriva A. PO-498 Quantifying the dynamics of acquired treatment resistance and evolutionary herding for the prediction of collateral sensitivity in cancer model systems. ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
15
|
Sundar R, Custodio A, Petruckevich A, Chénard-Poirier M, Ameratunga M, Collins D, Lim J, Kaye SB, Tunariu N, Banerji U, de Bono J, Lopez J. Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit. Clin Oncol (R Coll Radiol) 2018; 30:185-191. [PMID: 29224898 DOI: 10.1016/j.clon.2017.11.011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2017] [Revised: 10/19/2017] [Accepted: 11/22/2017] [Indexed: 11/25/2022]
Abstract
AIMS Advanced biliary tract carcinomas (ABC) are malignancies with limited effective therapies for advanced disease. There is little published evidence of outcomes of ABC patients participating in phase I clinical trials. MATERIALS AND METHODS Patient characteristics, treatment details and outcomes of ABC patients treated at a dedicated phase I unit were captured and analysed from case and trial records. RESULTS In total, 123 ABC patients were included in the study, of which 48 patients participated in 41 different phase I trials; 75 (61%) did not participate due to rapid disease progression or patient choice. Molecular characterisation of tumours using a targeted panel was conducted in 15 (31%), yielding several potentially actionable mutations, including BRCA, PIK3CA, FGFR, AKT and PTEN loss. Of the 39 evaluable patients there was one exceptional responder. Eighteen (46%) other patients achieved stable disease as their best response, with a clinical benefit rate at 4 months of 10%. Treatment was generally well tolerated with grade 3 or 4 adverse events only observed in eight patients (17 %), of which six were drug related and led to trial discontinuation in one (3%), with no toxicity-related deaths. CONCLUSION Carefully selected ABC patients have been found to tolerate experimental phase I clinical trials without excess toxicity. The aggressive nature of this disease warrants consideration of early referral to a phase I unit. Future work will require comprehensive molecular profiling in an attempt to understand the biology underlying the exceptional responders and to match patients in real-time to targeted therapies.
Collapse
Affiliation(s)
- R Sundar
- Royal Marsden Hospital & The Institute of Cancer Research, London, UK; National University Health System, Singapore
| | - A Custodio
- Royal Marsden Hospital & The Institute of Cancer Research, London, UK
| | - A Petruckevich
- Royal Marsden Hospital & The Institute of Cancer Research, London, UK
| | - M Chénard-Poirier
- Royal Marsden Hospital & The Institute of Cancer Research, London, UK
| | - M Ameratunga
- Royal Marsden Hospital & The Institute of Cancer Research, London, UK
| | - D Collins
- Royal Marsden Hospital & The Institute of Cancer Research, London, UK
| | - J Lim
- Royal Marsden Hospital & The Institute of Cancer Research, London, UK; National University Health System, Singapore
| | - S B Kaye
- Royal Marsden Hospital & The Institute of Cancer Research, London, UK
| | - N Tunariu
- Royal Marsden Hospital & The Institute of Cancer Research, London, UK
| | - U Banerji
- Royal Marsden Hospital & The Institute of Cancer Research, London, UK
| | - J de Bono
- Royal Marsden Hospital & The Institute of Cancer Research, London, UK
| | - J Lopez
- Royal Marsden Hospital & The Institute of Cancer Research, London, UK.
| |
Collapse
|
16
|
Banerji U, Stewart A, Coker E, Minchom A, Pölsterl S, Georgiou A, Al-Lazikani B. Unravelling the context specificity of signalling in KRAS mutant cancers: Implications for design of clinical trials. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy048.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
17
|
Plummer R, Halford S, Jones P, Wedge S, Hirschberg S, Veal G, Payne G, Chenard-Poirier M, Keun H, Banerji U. A first-in-human first-in-class (FIC) trial of the monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with advanced solid tumours. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy048.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
18
|
Smyth LM, Oliveira M, Ciruelos E, Tamura K, El-Khoueiry A, Mita A, You B, Renouf DJ, Sablin MP, Lluch A, Mayer IA, Bando H, Yamashita H, Ambrose H, de Bruin E, Carr TH, Corcoran C, Foxley A, Lindemann JPO, Maudsley R, Pass M, Rutkowski A, Schiavon G, Banerji U, Scaltriti M, Taylor BS, Chandarlapaty S, Baselga J, Hyman DM. Abstract P5-21-32: AZD5363 in combination with fulvestrant in AKT1-mutant ER-positive metastatic breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p5-21-32] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: E17K is the most common activating AKT1 mutation and was shown to be a therapeutic target in this multipart Phase 1 study of AZD5363 (NCT01226316), an oral and selective pan-AKT kinase inhibitor, in patients (pts) with AKT1-mutant (AKT1m) advanced solid tumors. In heavily pretreated AKT1m (E17K) ER+ metastatic breast cancer (MBC) pts, monotherapy achieved an objective response rate (ORR) of 20% and a median progression-free survival of 5.5 months (95% CI, 2.9−6.9). Suppression of PI3K-AKT signaling results in induction of ER-dependent transcription, potentially limiting the response to single-agent PI3K/AKT inhibitors. We explored the hypothesis that simultaneous inhibition of AKT and ER signaling would enhance antitumor efficacy in AKT1m ER+ MBC.
Methods: In an expansion of this study, we administered oral AZD5363 400 mg twice daily, 4 days on 3 days off, and fulvestrant 500 mg, to AKT1m (detected in tumor tissue by local screening and/or plasma BEAMing) ER+ HER2– MBC pts, enrolled into a fulvestrant-naïve (FN) or fulvestrant-resistant (FR) cohort (max 24 pts/cohort). Key objectives included safety and efficacy by RECIST v1.1. We report results of a planned interim analysis conducted when 12 pts/cohort reached maturity for assessment of 24-week clinical benefit rate (CBR), defined as the percentage of responders plus those with stable disease (SD) ≥24 weeks.Data cut-off occurred in June 2017.
Results: At the time of analysis, 24 AKT1m pts (23 E17K, 1 E40K) had received treatment. FN had more visceral disease (83.3% vs 66.7%) and ER+/PR– status (25% vs 8.3%) than FR. Median number of prior anticancer regimens was 4.5 (range 1–9) and 6 (2–11) in FN and FR, respectively, with more chemotherapy (CT) and less hormone therapy (HT) exposure in FN vs FR [3 (0–5) vs 2 (0–6) and 2 (0–4) vs 4 (2–6) prior CT and HT, respectively]. Prior palbociclib was received by 1 (8.3%) and 4 (33.3%) pts in FN and FR, respectively. Clinical efficacy is detailed below; CBR was 33% and 42% in FN and FR, respectively (Table 1). There was 1 unconfirmed partial response in patients treated with prior palbociclib and 3 SD. At data cut-off, 18 pts had discontinued treatment: progressive disease, n=12; adverse events (AEs), n=2; other reasons, n=4. AEs were observed in all 24 pts, most commonly diarrhea (71%), nausea (63%), vomiting and decreased appetite (29%). Grade ≥3 AEs occurred in 13 (54%) pts, most frequently maculopapular rash (n=3), nausea, hyperglycemia and back pain (all n=2). Dose reduction due to AEs occurred in 3 pts.
Table 1. Clinical efficacy FNFREligible for interim data cut-off, n1212ORR, n (%)2 (17)4 (33)CBR, n (%)4 (33)5 (42)Confirmed response (complete/partial response), n (%)2 (17)4 (33)SD ≥24 weeks, n (%)2 (17)1 (8)
Conclusions: AZD5363 plus fulvestrant is clinically active in AKT1m ER+ MBC pts, including in pts with demonstrated prior resistance to fulvestrant. Comparatively lower efficacy was observed in the FN cohort; factors that may have potentially contributed (eg disease characteristics) will be explored. cfDNA and genomic data will also be presented.
Citation Format: Smyth LM, Oliveira M, Ciruelos E, Tamura K, El-Khoueiry A, Mita A, You B, Renouf DJ, Sablin M-P, Lluch A, Mayer IA, Bando H, Yamashita H, Ambrose H, de Bruin E, Carr TH, Corcoran C, Foxley A, Lindemann JPO, Maudsley R, Pass M, Rutkowski A, Schiavon G, Banerji U, Scaltriti M, Taylor BS, Chandarlapaty S, Baselga J, Hyman DM. AZD5363 in combination with fulvestrant in AKT1-mutant ER-positive metastatic breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-21-32.
Collapse
Affiliation(s)
- LM Smyth
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - M Oliveira
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - E Ciruelos
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - K Tamura
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - A El-Khoueiry
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - A Mita
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - B You
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - DJ Renouf
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - M-P Sablin
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - A Lluch
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - IA Mayer
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - H Bando
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - H Yamashita
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - H Ambrose
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - E de Bruin
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - TH Carr
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - C Corcoran
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - A Foxley
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - JPO Lindemann
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - R Maudsley
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - M Pass
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - A Rutkowski
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - G Schiavon
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - U Banerji
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - M Scaltriti
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - BS Taylor
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - S Chandarlapaty
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - J Baselga
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - DM Hyman
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| |
Collapse
|
19
|
Smyth LM, Oliveira M, Ciruelos E, Tamura K, El-Khoueiry A, Mita A, You B, Renouf DJ, Sablin MP, Lluch A, Mayer IA, Bando H, Yamashita H, Ambrose H, de Bruin E, Carr TH, Corcoran C, Foxley A, Lindemann JPO, Maudsley R, Pass M, Rutkowski A, Schiavon G, Banerji U, Scaltriti M, Taylor BS, Chandarlapaty S, Baselga J, Hyman DM. Abstract P5-21-05: Withdrawn. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p5-21-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Collapse
Affiliation(s)
- LM Smyth
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - M Oliveira
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - E Ciruelos
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - K Tamura
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - A El-Khoueiry
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - A Mita
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - B You
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - DJ Renouf
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - M-P Sablin
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - A Lluch
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - IA Mayer
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - H Bando
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - H Yamashita
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - H Ambrose
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - E de Bruin
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - TH Carr
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - C Corcoran
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - A Foxley
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - JPO Lindemann
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - R Maudsley
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - M Pass
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - A Rutkowski
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - G Schiavon
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - U Banerji
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - M Scaltriti
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - BS Taylor
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - S Chandarlapaty
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - J Baselga
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - DM Hyman
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| |
Collapse
|
20
|
Ingles Garces A, Ang J, Ameratunga M, Chenard-Poirier M, Dolling D, Diamantis N, Seeramreddi S, Sundar R, de Bono J, Lopez J, Banerji U. Drug-induced electrolyte abnormalities in oncology phase I trials: Analysis of 1088 cases treated at The Royal Marsden Hospital. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx367.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
21
|
Coleman N, Michalarea V, Alken S, Perez Lopez R, Tunariu N, Petruckevitch A, Banerji U, de Bono J, Welsh L, Saran F, Lopez J. Prognostic Impact of neutrophil to lymphocyte ratio (NLR) in patients (pts) with recurrent primary malignant brain tumours (PMBT) in phase I (Ph1) trials: The Royal Marsden (RMH) Experience. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx366.020] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
22
|
Ingles Garces A, Ang J, Ameratunga M, Chenard-Poirier M, Dolling D, Sundar R, Kaye S, de Bono J, Banerji U, Lopez J. Impact of prior immune checkpoint inhibitors on haematological toxicity in phase I patients receiving chemotherapy. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx376.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
23
|
Vormoor B, Veal GJ, Griffin MJ, Boddy AV, Irving J, Minto L, Case M, Banerji U, Swales KE, Tall JR, Moore AS, Toguchi M, Acton G, Dyer K, Schwab C, Harrison CJ, Grainger JD, Lancaster D, Kearns P, Hargrave D, Vormoor J. A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia. Pediatr Blood Cancer 2017; 64. [PMID: 27905678 DOI: 10.1002/pbc.26351] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/18/2016] [Accepted: 10/07/2016] [Indexed: 01/21/2023]
Abstract
Aurora kinases regulate mitosis and are commonly overexpressed in leukemia. This phase I/IIa study of AT9283, a multikinase inhibitor, was designed to identify maximal tolerated doses, safety, pharmacokinetics, and pharmacodynamic activity in children with relapsed/refractory acute leukemia. The trial suffered from poor recruitment and terminated early, therefore failing to identify its primary endpoints. AT9283 caused tolerable toxicity, but failed to show clinical responses. Future trials should be based on robust preclinical data that provide an indication of which patients may benefit from the experimental agent, and recruitment should be improved through international collaborations and early combination with established treatment strategies.
Collapse
Affiliation(s)
- B Vormoor
- Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK
- Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
| | - G J Veal
- Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK
| | - M J Griffin
- Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK
| | - A V Boddy
- Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK
| | - J Irving
- Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK
| | - L Minto
- Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK
| | - M Case
- Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK
| | - U Banerji
- Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, U.K
- The Royal Marsden Hospital, Sutton, UK
| | - K E Swales
- Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, U.K
| | - J R Tall
- Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, U.K
| | - A S Moore
- Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, U.K
- The Royal Marsden Hospital, Sutton, UK
| | - M Toguchi
- Astex Pharmaceuticals, Cambridge Science Park, Cambridge, UK
| | - G Acton
- Cancer Research UK Centre for Drug Development, London, UK
| | - K Dyer
- Cancer Research UK Centre for Drug Development, London, UK
| | - C Schwab
- Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK
| | - C J Harrison
- Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK
| | - J D Grainger
- Royal Manchester Children's Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
- Faculty of Medical & Human Sciences, University of Manchester, Manchester, UK
| | | | - P Kearns
- Institute of Cancer and Genomic Medicine, University of Birmingham, Birmingham, UK
| | - D Hargrave
- Great Ormond Street Hospital for Children, London, UK
| | - J Vormoor
- Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK
- Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
| |
Collapse
|
24
|
Sundar R, Custodio A, Lim J, Chenard-Poirier M, Collins D, Kaye S, Yap T, Banerji U, Lopez J, de Bono J. Clinical outcome of patients with advanced biliary tract cancer in a dedicated phase 1 unit. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw368.47] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
25
|
Khan KH, Yap TA, Ring A, Molife LR, Bodla S, Thomas K, Zivi A, Smith A, Judson I, Banerji U, de Bono JS, Kaye SB. Phase I trial outcomes in older patients with advanced solid tumours. Br J Cancer 2016; 114:262-8. [PMID: 26757260 PMCID: PMC4742590 DOI: 10.1038/bjc.2015.477] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2015] [Revised: 12/10/2015] [Accepted: 12/14/2015] [Indexed: 01/20/2023] Open
Abstract
Background: This study had two aims: (a) to test the hypothesis that advanced age is associated with lower levels of tolerability and clinical benefit to experimental Phase I trial agents; (b) to assess the validity of the Royal Marsden Hospital (RMH) prognostic score as a patient selection tool in older patients. Methods: Clinico-pathological characteristics and treatment outcomes of all patients treated consecutively from 2005 to 2009 in phase I trials at the RMH were recorded. All toxicity and clinical outcome data were compared between patients aged below and above 65 years of age. Results: One thousand and four patients were treated in 30 Phase I trials, with 315 (31%) patients aged 65 years and older. Grade 3–5 toxicities (22.8% vs 24.8% (P=0.52)), trial discontinuation (6% vs 4% P=0.33), and dose interruptions (8.0% vs 8.0% (P=0.96)) were observed at similar rates in patients below and above 65 years of age, respectively. The overall response rate 5.2% vs 4.1%, progression-free survival (PFS) 1.9 vs 3.5 months and clinical benefit rate (CBR) at 6 months 15.2% vs 14.3% were comparable in both groups. To avoid bias due to the potential therapeutic benefit of abiraterone, comparisons were repeated excluding prostate cancer patients with similar results (ORR 4.6% vs 4%, PFS 1.8 vs 3.0 months, CBR at 6 months 13.5% vs 9.5%). Multivariate analysis indicated that the previously identified RMH score (including albumin and lactate dehydrogenase levels) was an accurate predictor of outcome. Conclusions: Phase I clinical trials should be considered in patients with advanced cancers regardless of age, as older patients who enter these have similar safety and efficacy outcomes as their younger counterparts. The RMH prognostic score can assist in the selection of suitable older patients.
Collapse
Affiliation(s)
- K H Khan
- Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton SM2 5PT, UK.,Gastrointestinal Cancers Unit, The Royal Marsden NHS Foundation Trust, Sutton SM2 5PT, UK
| | - T A Yap
- Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton SM2 5PT, UK.,Division of Clinical Studies, The Institute of Cancer Research, Sutton SM2 5NG, UK
| | - A Ring
- Breast Unit, The Royal Marsden NHS Foundation Trust, Sutton SM2 5PT, UK
| | - L R Molife
- Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton SM2 5PT, UK
| | - S Bodla
- Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton SM2 5PT, UK
| | - K Thomas
- Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton SM2 5PT, UK
| | - A Zivi
- Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton SM2 5PT, UK
| | - A Smith
- Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton SM2 5PT, UK
| | - I Judson
- Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton SM2 5PT, UK
| | - U Banerji
- Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton SM2 5PT, UK.,Division of Clinical Studies, The Institute of Cancer Research, Sutton SM2 5NG, UK
| | - J S de Bono
- Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton SM2 5PT, UK.,Division of Clinical Studies, The Institute of Cancer Research, Sutton SM2 5NG, UK
| | - S B Kaye
- Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton SM2 5PT, UK.,Division of Clinical Studies, The Institute of Cancer Research, Sutton SM2 5NG, UK
| |
Collapse
|
26
|
Van Herpen C, Banerji U, Mommers E, Koper N, Goedings P, Lopez J, Awada A, Fiebrich H, Aftimos P. 333 Phase I dose-escalation trial with the DNA-alkylating anti-HER2 antibody-drug conjugate SYD985. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30197-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
27
|
Papadatos-Pastos D, Roda D, Luken MDM, Jalil A, Diamantis N, Michalarea V, Lima J, Capelan M, Bodla S, Bhosle J, Molife R, O'Brien M, Banerji U, Popat S, Yap T. 339 Clinical outcome and prognostic factors of patients (pts) with relapsed mesothelioma on phase I trials in the Drug Development Unit (DDU) of the Royal Marsden Hospital (RMH). Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30202-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
28
|
Michalarea V, Lopez J, Lorente D, Carreira S, Hassam H, Parmar M, Turner A, Hall E, Fandos SS, Decordova S, Swales K, Ruddle R, Raynaud F, Tunariu N, Stephens C, Molife L, Banerji U, Plummer R, Bono JD, Yap T. 343 Translational phase I trial combining the AKT inhibitor AZD5363 (AZD) and PARP inhibitor Olaparib (Ola) in advanced cancer patients (pts). Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30206-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
29
|
Stewart A, Thavasu P, de Bono JS, Banerji U. Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors. Ann Oncol 2015; 26:1504-10. [PMID: 25908604 PMCID: PMC4478974 DOI: 10.1093/annonc/mdv188] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2014] [Accepted: 04/13/2015] [Indexed: 02/06/2023] Open
Abstract
Our results show that sub-optimal inhibition of MEK in combination with AKT is less efficient in inhibiting cellular growth compared to completely inhibiting MEK and AKT alone. The results also show that KRAS mutant cells are more sensitive to a combination of MEK and AKT inhibitors compared to BRAF and PIK3CA mutant cells. Both these findings have clinical implications. Background We aimed to understand the relative contributions of inhibiting MEK and AKT on cell growth to guide combinations of these agents. Materials and methods A panel of 20 cell lines was exposed to either the MEK inhibitor, PD0325901, or AKT inhibitor, AKT 1/2 inhibitor. p-ERK and p-S6 ELISAs were used to define degrees of MEK and AKT inhibition, respectively. Growth inhibition to different degrees of MEK and AKT inhibition, either singly or in combination using 96-h sulphorhodamine assays was then studied. Results A significantly greater growth inhibition was seen in BRAFM and PIK3CAM cells upon maximal MEK (P = 0.004) and AKT inhibition (P = 0.038), respectively. KRASM and BRAF/PIK3CA/KRASWT cells were not significantly more likely to be sensitive to MEK or AKT inhibition. Significant incremental growth inhibition of the combination of MEK + AKT over either MEK or AKT inhibition alone was seen when MEK + AKT was inhibited maximally and not when sub-maximal inhibition of both MEK + AKT was used (11/20 cell lines versus 1/20 cell lines; P = 0.0012). Conclusions KRASM cells are likely to benefit from combinations of MEK and AKT inhibitors. Sub-maximally inhibiting both MEK and AKT within a combination, in a majority of instances, does not significantly increase growth inhibition compared with maximally inhibiting MEK or AKT alone and alternative phase I trial designs are needed to clinically evaluate such combinations.
Collapse
Affiliation(s)
- A Stewart
- Division of Cancer Therapeutics/Division of Clinical Studies, The Institute of Cancer Research, London
| | - P Thavasu
- Division of Cancer Therapeutics/Division of Clinical Studies, The Institute of Cancer Research, London
| | - J S de Bono
- Division of Cancer Therapeutics/Division of Clinical Studies, The Institute of Cancer Research, London The Royal Marsden, London, UK
| | - U Banerji
- Division of Cancer Therapeutics/Division of Clinical Studies, The Institute of Cancer Research, London The Royal Marsden, London, UK
| |
Collapse
|
30
|
|
31
|
Frenel J, Carreira S, Goodall J, Roda-Perez D, Smith A, Mateo J, Ong M, Gasi-Tandefelt D, Yap T, Attard G, Nava-Rodrigues D, Molife L, Kaye S, Banerji U, de Bono J. Serial Next Generation Sequencing of Cfdna to Monitor Phase I Targeted Drug Administration. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu438.1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
32
|
Basu B, Roda-Perez D, Wong H, Sathiyayogan N, Parmar M, Turner A, Swales K, Stimpson S, Hall E, Hategan M, Garcia-Corbacho J, Yap T, Molife L, Jimenez B, Banerjee S, Kaye S, De Bono J, Banerji U. Phase I Multicentre Tax-Torc Trial of the Dual Mtorc1/2 Inhibitor Azd2014 (A) Plus Weekly Paclitaxel (P) in Patients (Pts) with Solid Tumours (Crukd/12/013). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu331.28] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
33
|
Banerji U. Targets, Targets Everywhere but not a Drug to Give. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu294.4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
34
|
Capelan M, Roda D, Geuna E, Rihawi K, Shankar B, Kaye S, Bhosle J, Molife L, Banerji U, Óbrien M, De Bono J, Popat S, Yap T. Clinical Outcome of Advanced Non-Small Cell Lung Cancer Patients (Ansclc Pts) on Phase I Trials in the Drug Development Unit (Ddu) at the Royal Marsden Hospital (Rmh). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
35
|
Puglisi M, Thavasu P, Stewart A, de Bono JS, O'Brien MER, Popat S, Bhosle J, Banerji U. AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines. Lung Cancer 2014; 85:141-6. [PMID: 24957682 DOI: 10.1016/j.lungcan.2014.05.008] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2014] [Revised: 05/07/2014] [Accepted: 05/08/2014] [Indexed: 01/13/2023]
Abstract
OBJECTIVES EGFR inhibitors are ineffective against most EGFR wild-type non-small cell lung cancer, for which novel treatment strategies are needed. AKT signalling is essential for mediating EGFR survival signals in NSCLC. We evaluated the combination of gefitinib and two different AKT inhibitors, the allosteric inhibitor AKTi-1/2 and the ATP-competitive pan-AKT inhibitor AZD5363, in EGFR-mutant (HCC-827 and PC-9) and -wild-type (NCI-H522, NCI-H1651), non-small cell lung cancer cell lines. MATERIALS AND METHODS Drug interaction was studied in two EGFR mutant and two EGFR wild-type non-small cell lung cancer cell lines by calculating combination index (CI) using median effect analysis. The effects on p-EGFR, p-ERK, p-AKT, p-S6 and apoptosis were studied by Western blot analysis. RESULTS The combination of gefitinib and AKTi-1/2 or AZD5363 showed synergistic growth inhibition in all cell lines. CI values for the combination of gefitinib and AKTi-1/2 were 0.35 (p=0.0048), 0.56 (p=0.036), 0.75 (p=0.13) and 0.64 (p=0.0003) in NCI-H522, NCI-H1651, HCC-827 and PC-9 cell lines, respectively; CI values of 0.45 (p=0.0087) and 0.22 (p<0.0001) were observed in NCI-H522 and PC-9 cells, respectively, when gefitinib was combined with AZD5363. Additive inhibition of signalling output through AKT and key downstream proteins (S6) and increased apoptosis were demonstrated. CONCLUSION Dual inhibition of EGFR and AKT may be a useful up-front strategy for patients with EGFR-mutant and -wild-type non-small cell lung cancer.
Collapse
Affiliation(s)
- M Puglisi
- The Drug Development Unit, Divisions of Cancer Therapeutics & Clinical Studies, The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust, London, UK; The Lung Unit, The Royal Marsden NHS Foundation Trust, London, UK
| | - P Thavasu
- The Drug Development Unit, Divisions of Cancer Therapeutics & Clinical Studies, The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust, London, UK
| | - A Stewart
- The Drug Development Unit, Divisions of Cancer Therapeutics & Clinical Studies, The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust, London, UK
| | - J S de Bono
- The Drug Development Unit, Divisions of Cancer Therapeutics & Clinical Studies, The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust, London, UK
| | - M E R O'Brien
- The Lung Unit, The Royal Marsden NHS Foundation Trust, London, UK
| | - S Popat
- The Lung Unit, The Royal Marsden NHS Foundation Trust, London, UK
| | - J Bhosle
- The Lung Unit, The Royal Marsden NHS Foundation Trust, London, UK
| | - U Banerji
- The Drug Development Unit, Divisions of Cancer Therapeutics & Clinical Studies, The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust, London, UK.
| |
Collapse
|
36
|
Chen DS, Feltquate DM, Smothers F, Hoos A, Langermann S, Marshall S, May R, Fleming M, Hodi FS, Senderowicz A, Wiman KG, de Dosso S, Fiedler W, Gianni L, Cresta S, Schulze-Bergkamen HB, Gurrieri L, Salzberg M, Dietrich B, Danielczyk A, Baumeister H, Goletz S, Sessa C, Strumberg D, Schultheis B, Santel A, Gebhardt F, Meyer-Sabellek W, Keil O, Giese K, Kaufmann J, Maio M, Choy G, Covre A, Parisi G, Nicolay H, Fratta E, Fonsatti E, Sigalotti L, Coral S, Taverna P, Azab M, Deutsch E, Lepechoux C, Pignon JP, Tao YT, Rivera S, Bourgier BC, Angokai M, Bahleda R, Slimane K, Angevin E, Besse BB, Soria JC, Dragnev K, Beumer JH, Anyang B, Ma T, Galimberti F, Erkmen CP, Nugent W, Rigas J, Abraham K, Johnstone D, Memoli V, Dmitrovsky E, Voest EE, Siu L, Janku F, Soria JC, Tsimberidou A, Kurzrock R, Tabernero J, Rodon J, Berger R, Onn A, Batist G, Bresson C, Lazar V, Molenaar JJ, Koster J, Ebus M, Zwijnenburg DA, van Sluis P, Lamers F, Schild L, van der Ploeg I, Caron HN, Versteeg R, Pouyssegur J, Marchiq I, Chiche J, Roux D, Le Floch R, Critchlow SE, Wooster RF, Agresta S, Yen KE, Janne PA, Plummer ER, Trinchieri G, Ellis L, Chan SL, Yeo W, Chan AT, Mouliere F, El Messaoudi S, Gongora C, Lamy PJ, del Rio M, Lopez-Crapez E, Gillet B, Mathonnet M, Pezet D, Ychou M, Thierry AR, Ribrag V, Vainchenker W, Constantinescu S, Keilhack H, Umelo IA, Noeparast A, Chen G, Renard M, Geers C, Vansteenkiste J, Teugels E, de Greve J, Rixe O, Qi X, Chu Z, Celerier J, Leconte L, Minet N, Pakradouni J, Kaur B, Cuttitta F, Wagner AJ, Zhang YX, Sicinska E, Czaplinski JT, Remillard SP, Demetri GD, Weng S, Debussche L, Agoni L, Reddy EP, Guha C, Silence K, Thibault A, de Haard H, Dreier T, Ulrichts P, Moshir M, Gabriels S, Luo J, Carter C, Rajan A, Khozin S, Thomas A, Lopez-Chavez A, Brzezniak C, Doyle L, Keen C, Manu M, Raffeld M, Giaccone G, Lutzker S, Melief JM, Eckhardt SG, Trusolino L, Migliardi G, Zanella ER, Cottino F, Galimi F, Sassi F, Marsoni S, Comoglio PM, Bertotti A, Hidalgo M, Weroha SJ, Haluska P, Becker MA, Harrington SC, Goodman KM, Gonzalez SE, al Hilli M, Butler KA, Kalli KR, Oberg AL, Huijbers IJ, Bin Ali R, Pritchard C, Cozijnsen M, Proost N, Song JY, Krimpenfort P, Michalak E, Jonkers J, Berns A, Banerji U, Stewart A, Thavasu P, Banerjee S, Kaye SB. Lectures. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
37
|
Banerji U, Stewart A, Thavasu P, Banerjee S, Kaye S. Human Cancer Cells Isolated from Ascites as Models to Optimize the Use of Targeted Anticancer Agents in Ovarian Cancer. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt042.53] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
38
|
Michie C, Ong M, Mateo J, Young A, Olmos D, Ang J, Molife L, Banerji U, de Bono J, Kaye S. The Clinical Utility of a Change in the Royal Marsden Hospital Prognostic Score (RMHPS) in Patients (PTS) Prior to Phase I Clinical Trial Therapy. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33029-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
39
|
Naing A, Aghajanian C, Raymond E, Olmos D, Schwartz G, Oelmann E, Grinsted L, Burke W, Taylor R, Kaye S, Kurzrock R, Banerji U. Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. Br J Cancer 2012; 107:1093-9. [PMID: 22935583 PMCID: PMC3461162 DOI: 10.1038/bjc.2012.368] [Citation(s) in RCA: 95] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
Background: This study assessed the safety, tolerability, pharmacokinetics and pharmacodynamics of the first-in-class dual mammalian target of rapamycin complex (mTORC)1/mTORC2 inhibitor, AZD8055. Methods: Patients with advanced solid malignancies or lymphomas were recruited into this phase I, open-label, dose-escalation study of AZD8055 starting at 10 mg twice-daily oral dosing (BID). Results: Forty-nine patients received AZD8055. Dose-limiting toxicities were reported at 40 mg (n=1), 90 mg (n=1) and 120 mg (n=3) BID; all were grade 3 rises in transaminases, reversible in all patients, apart from one who had liver metastases. The maximum tolerated dose was defined as 90 mg BID. The most frequent adverse events assessed to be related to AZD8055 were increased alanine aminotransferase (22%), increased aspartate aminotransferase (22%) and fatigue (16%). AZD8055 was rapidly absorbed (median tmax ∼0.5 h) and exposure increased with increasing doses. Seven patients had stable disease for ⩾4 months. Partial metabolic responses, assessed by fluorodeoxyglucose positron emission tomography, were observed at ⩾40 mg BID (n=8 at day 35). Conclusion: The maximum tolerated dose for AZD8055 is 90 mg BID. Apart from elevated transaminases, which occurred at most dose levels, the drug had an acceptable toxicity profile; however, no RECIST responses were seen.
Collapse
Affiliation(s)
- A Naing
- The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Basu B, Vitfell-Pedersen J, Moreno Garcia V, Puglisi M, Tjokrowidjaja A, Shah K, Malvankar S, Anghan B, de Bono JS, Kaye SB, Molife LR, Banerji U. Creatinine clearance is associated with toxicity from molecularly targeted agents in phase I trials. Oncology 2012; 83:177-82. [PMID: 22889980 PMCID: PMC5079100 DOI: 10.1159/000341152] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2012] [Accepted: 06/18/2012] [Indexed: 11/19/2022]
Abstract
Objectives This study aimed to evaluate any correlations between baseline creatinine clearance and the development of grade 3/4 toxicities during treatment within oncology phase I trials of molecularly targeted agents where entry criteria mandate a serum creatinine of ≤1.5 × the upper limit of normal. Methods Documented toxicity and creatinine clearance (calculated by the Cockcroft-Gault formula) from all patients treated with molecularly targeted agents in the context of phase I trials within our centre over a 5-year period were analyzed. Results Data from 722 patients were analyzed; 116 (16%) developed at least one episode of grade 3/4 toxicity. Patients who developed a late-onset (>1 cycle) grade 3/4 toxicity had a lower creatinine clearance than those who did not (82.69 ml/min vs. 98.97 ml/min; p = < 0.001). Conclusion Creatinine clearance (even when within normal limits) should be studied as a potential factor influencing late toxicities in the clinical trials of molecularly targeted anti-cancer drugs.
Collapse
Affiliation(s)
- B Basu
- Drug Development Unit, Division of Clinical Studies, The Institute of Cancer Research/The Royal Marsden NHS Foundation Trust, Sutton, UK
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Molife LR, Alam S, Olmos D, Puglisi M, Shah K, Fehrmann R, Trani L, Tjokrowidjaja A, de Bono JS, Banerji U, Kaye SB. Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience. Ann Oncol 2012; 23:1968-1973. [PMID: 22408187 DOI: 10.1093/annonc/mds030] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND This study defined the risk of serious toxicity in phase I trials of molecularly targeted agents (MTA). PATIENTS AND METHODS A retrospective analysis of toxicity data from patients treated in phase I trials of MTAs was carried out to define the rate of treatment-related grade 3/4 toxic effects, deaths and risk factors associated with grade 3 or more toxicity. RESULTS Data from 687 patients [median age, 59.1 years (range 12.5-85.5)] treated in 36 trials were analysed. Two hundred and eleven patients were of Eastern Cooperative Oncology Group performance status (PS) zero, 432 of PS one, 38 of PS two and 6 unknown. The rate of grade 3 and 4 events was 14.1% (n=97) and 1.9% (n=13), respectively. Twenty-four percent of events were gastrointestinal, 22% constitutional and 20% metabolic. PS two was associated with a higher risk of toxicity [odds ratio (OR), 2.6; 95% confidence interval (CI) 1.1-6.1; P=0.032] as was receiving >100% of maximum tolerated dose or maximum administered dose (OR 2.5; CI 1.6-3.9; P<0.001). Mortality rate was 0.43% (n=3). CONCLUSIONS Therapy with novel MTAs in phase I trials is associated with a moderate risk of significant toxicity. This appears less than in phase I studies involving cytotoxic agents, particularly in relation to grade 4 toxicity. The risk of death is low.
Collapse
Affiliation(s)
- L R Molife
- Drug Development Unit, Royal Marsden/Institute of Cancer Research, Sutton, UK.
| | - S Alam
- Drug Development Unit, Royal Marsden/Institute of Cancer Research, Sutton, UK
| | - D Olmos
- Drug Development Unit, Royal Marsden/Institute of Cancer Research, Sutton, UK
| | - M Puglisi
- Drug Development Unit, Royal Marsden/Institute of Cancer Research, Sutton, UK
| | - K Shah
- Drug Development Unit, Royal Marsden/Institute of Cancer Research, Sutton, UK
| | - R Fehrmann
- Drug Development Unit, Royal Marsden/Institute of Cancer Research, Sutton, UK
| | - L Trani
- Drug Development Unit, Royal Marsden/Institute of Cancer Research, Sutton, UK
| | - A Tjokrowidjaja
- Drug Development Unit, Royal Marsden/Institute of Cancer Research, Sutton, UK
| | - J S de Bono
- Drug Development Unit, Royal Marsden/Institute of Cancer Research, Sutton, UK
| | - U Banerji
- Drug Development Unit, Royal Marsden/Institute of Cancer Research, Sutton, UK
| | - S B Kaye
- Drug Development Unit, Royal Marsden/Institute of Cancer Research, Sutton, UK
| |
Collapse
|
42
|
Vitfell-Pedersen J, Basu B, Moreno V, Tjokrowidjaja A, Puglisi M, Shah K, Malvankar S, Alam S, Molife R, Banerji U. 1232 POSTER Creatinine Clearance (CrCI) as a Predictive Marker for the Risk of Toxicity From Molecularly Targeted Agents (MTA) in Phase I Trials. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)70844-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
43
|
Omlin A, Venugopal B, Kristeleit R, Shah K, Fourneau N, Hellemans P, de Bono J, Plummer R, Banerji U, Evans J. 1234 POSTER A First in Man Phase 1 Study of JNJ-26481585, a Novel Oral Histone Deacetylase Inhibitor (HDACi) in Advanced Cancer Patients -Evidence of Target Modulation, Antitumour Activity and Additional Safety Data in an Expanded Patient Cohort. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)70846-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
44
|
Blanco-Codesido M, Brunetto A, Frentzas S, Moreno Garcia V, Papadatos-Pastos D, Pedersen JV, Trani L, Puglisi M, Sarker D, Molife LR, Banerji U. Clinical outcome of patients with metastasic melanoma undergoing phase I clinical trials. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.8564] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
45
|
Baird RD, Venugopal B, Kristeleit RS, Charlton J, Blanco-Codesido M, Saunders E, Shah KJ, Crawford D, Stephens P, Wilkins D, Sweeting L, Forslund A, Smit JW, Palmer PA, Fourneau N, Hellemans P, De Bono JS, Plummer R, Banerji U, Evans TRJ. A first-in-human phase I study of JNJ-26481585, a novel oral histone deacetylase inhibitor (HDACi), in patients with advanced cancer with evidence of target modulation and antitumor activity. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3024] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
46
|
Banerji U, Aghajanian C, Raymond E, Kurzrock R, Blanco-Codesido M, Oelmann E, Grinsted L, Burke W, Kaye SB, Naing A. First results from a phase I trial of AZD8055, a dual mTORC1 and mTORC2 inhibitor. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3096] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
47
|
Schroder CP, Pedersen JV, Chua S, Swanton C, Akimov M, Ide S, Fernandez-Ibarra C, Dzik-Jurasz A, De Vries E, Gaykema SB, Banerji U. Use of biomarkers and imaging to evaluate the treatment effect of AUY922, an HSP90 inhibitor, in patients with HER2+ or ER+ metastatic breast cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e11024] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
48
|
Ang JE, Olmos D, Moreno Garcia V, Brunetto A, Papadatos-Pastos D, Arkenau H, Blanco M, Baird RD, Cassier PA, Tan DSW, Kristeleit RS, Dolly S, Shah KJ, Amin B, Anghan BG, Molife LR, Banerji U, De Bono JS, Kaye SB. Utility of novel dynamic clinical indices in patients (pts) enrolled in a phase I (Ph I) oncology trial as markers of prognosis and treatment benefit. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.2555] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
49
|
Dolly SO, Albanell J, Kraeber-Bodere F, Banerji U, Bahleda R, Martinez Garcia M, Xu ZX, Guarin E, Tessier J, Shochat E, Deutsch J, Blotner S, Meresse V, Soria J. First-in-human, safety, pharmacodynamic (PD) and pharmacokinetic (PK) trial of a first-in-class dual RAF/MEK inhibitor, RO5126766, in patients with advanced or metastatic solid tumors. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3006] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
50
|
Eskens F, van Doorn L, Papadatos-Pastos D, Debnam P, Tall M, Toal M, Hooftman L, Verweij J, Banerji U. 394 A phase I dose escalation and pharmacological study of the novel class I selective histone deacetylase inhibitor CHR-3996, in patients with advanced or treatment refractory solid tumours. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)72101-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|